Acorda Therapeutics, Inc. (ACOR): Price and Financial Metrics

Acorda Therapeutics, Inc. (ACOR): $0.52

-0.04 (-7.14%)

POWR Rating

Component Grades













Add ACOR to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where ACOR ranks best; there it ranks ahead of 80.57% of US stocks.
  • The strongest trend for ACOR is in Growth, which has been heading down over the past 106 days.
  • ACOR ranks lowest in Growth; there it ranks in the 7th percentile.

ACOR Stock Summary

  • ACOR has a higher market value than only 3.78% of US stocks; more precisely, its current market capitalization is $22,127,994.
  • With a price/sales ratio of 0.17, Acorda Therapeutics Inc has a higher such ratio than merely 2.3% of stocks in our set.
  • Acorda Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 314.78%, greater than the shareholder yield of 99.1% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Acorda Therapeutics Inc, a group of peers worth examining would be AXTA, TWI, ENR, CVV, and FLWS.
  • Visit ACOR's SEC page to see the company's official filings. To visit the company's web site, go to

ACOR Valuation Summary

  • ACOR's price/earnings ratio is -0.4; this is 101.1% lower than that of the median Healthcare stock.
  • ACOR's price/earnings ratio has moved up 1.7 over the prior 189 months.
  • Over the past 189 months, ACOR's price/earnings ratio has gone up 1.7.

Below are key valuation metrics over time for ACOR.

Stock Date P/S P/B P/E EV/EBIT
ACOR 2021-08-31 0.3 0.2 -0.4 -1.5
ACOR 2021-08-30 0.3 0.2 -0.3 -1.5
ACOR 2021-08-27 0.3 0.2 -0.4 -1.5
ACOR 2021-08-26 0.3 0.2 -0.4 -1.5
ACOR 2021-08-25 0.3 0.2 -0.4 -1.5
ACOR 2021-08-24 0.3 0.2 -0.3 -1.5

ACOR Growth Metrics

    Its year over year cash and equivalents growth rate is now at 95.67%.
  • The 5 year cash and equivalents growth rate now stands at -82.42%.
  • Its 3 year net cashflow from operations growth rate is now at -18.06%.
ACOR's revenue has moved down $280,334,000 over the prior 34 months.

The table below shows ACOR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 129.071 -41.348 -103.954
2021-09-30 130.263 -43.14 -166.434
2021-06-30 151.897 -37.033 -132.016
2021-03-31 153.73 -49.115 -126.573
2020-12-31 152.967 -61.006 -99.594
2020-09-30 165.304 -73.883 49.114

ACOR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACOR has a Quality Grade of C, ranking ahead of 72.56% of graded US stocks.
  • ACOR's asset turnover comes in at 0.251 -- ranking 176th of 680 Pharmaceutical Products stocks.
  • BDSI, INVA, and CALA are the stocks whose asset turnover ratios are most correlated with ACOR.

The table below shows ACOR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.251 0.695 -0.414
2021-03-31 0.232 0.729 -0.327
2020-12-31 0.217 0.781 -0.207
2020-09-30 0.221 0.810 0.173
2020-06-30 0.202 0.830 -0.419
2020-03-31 0.194 0.831 -0.393

ACOR Price Target

For more insight on analysts targets of ACOR, see our ACOR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.5 (Moderate Buy)

ACOR Stock Price Chart Interactive Chart >

Price chart for ACOR

ACOR Price/Volume Stats

Current price $0.52 52-week high $6.36
Prev. close $0.55 52-week low $0.49
Day low $0.49 Volume 475,300
Day high $0.60 Avg. volume 88,154
50-day MA $1.38 Dividend yield N/A
200-day MA $2.75 Market Cap 6.84M

Acorda Therapeutics, Inc. (ACOR) Company Bio

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The company was founded in 1995 and is based in Ardsley, New York.

ACOR Latest News Stream

Event/Time News Detail
Loading, please wait...

ACOR Latest Social Stream

Loading social stream, please wait...

View Full ACOR Social Stream

Latest ACOR News From Around the Web

Below are the latest news stories about Acorda Therapeutics Inc that investors may wish to consider to help them evaluate ACOR as an investment opportunity.

Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

ARDSLEY, N.Y., January 04, 2022--Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Yahoo | January 4, 2022

John Varian Joins Acorda Therapeutics Board of Directors

ARDSLEY, N.Y., January 03, 2022--John Varian joins Acorda Therapeutics Board of Directors

Yahoo | January 3, 2022

Multiple Sclerosis Market to Witness Notable Growth by 2027 Covid-19 Analysis | Abbvie, Acorda Therapeutics

This Multiple Sclerosis market report describes the factors that contribute to the sector''s development as well as market channels. When taken in order, this Multiple Sclerosis market report starts with an introduction to the commercial chain structure and then moves

OpenPR | December 15, 2021

Ataxia Market Expected to Expand at a Steady 2021-2028 | Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc.

"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are

OpenPR | December 13, 2021

Global Multiple Sclerosis Drugs Market Research Report 2021 Featuring Biogen, Novartis, Roche, Bayer HealthCare, Pfizer., Merck & Co, Sanofi, Teva Pharm, GSK and Acorda Therapeutics -

DUBLIN--(BUSINESS WIRE)--The "Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to''s offering. The global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $22.04 billion in 2021 at a compound annual growth rate (CAGR) of 3.6%. The market is expected to reach $25.95 billion in 2025 at a CAGR of 4%. Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, B

Business Wire | December 13, 2021

Read More 'ACOR' Stories Here

ACOR Price Returns

1-mo -65.56%
3-mo -74.63%
6-mo -85.01%
1-year -87.41%
3-year -99.21%
5-year -99.43%
YTD -78.24%
2021 -42.28%
2020 -66.17%
2019 -86.91%
2018 -27.37%
2017 14.10%

Continue Researching ACOR

Here are a few links from around the web to help you further your research on Acorda Therapeutics Inc's stock as an investment opportunity:

Acorda Therapeutics Inc (ACOR) Stock Price | Nasdaq
Acorda Therapeutics Inc (ACOR) Stock Quote, History and News - Yahoo Finance
Acorda Therapeutics Inc (ACOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8377 seconds.